Common Contracts
8 similar Executive Change in Control Agreement contracts by GTC Biotherapeutics Inc
EX-10.2.1 2 dex1021.htm EXECUTIVE CHANGE IN CONTROL AGREEMENT, AND DANIEL S.WOLOSHEN. EXECUTIVE CHANGE IN CONTROL AGREEMENTExecutive Change in Control Agreement • May 5th, 2020 • Massachusetts
This Executive Change in Control Agreement (this “Agreement”) is dated as of August 16, 2004 by and between GTC Biotherapeutics, Inc. (the “Company”), a Massachusetts corporation with its principal executive offices at 175 Crossing Boulevard, 4th Floor, Suite 410, Framingham, MA 01702-9322; and Daniel S. Woloshen (“Executive”).
AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AGREEMENTExecutive Change in Control Agreement • August 7th, 2008 • GTC Biotherapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Executive Change in Control Agreement (this “Agreement”) is dated as of July 23, 2008 by and between GTC Biotherapeutics, Inc. (the “Company”), a Massachusetts corporation with its principal executive offices at 175 Crossing Boulevard, 4th Floor, Suite 410, Framingham, MA 01702-9322; and Richard A. Scotland (“Executive”) hereby amends and restates in its entirety that Executive Change in Control Agreement dated August 1, 2006 between the Company and the Executive.
AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AGREEMENTExecutive Change in Control Agreement • August 7th, 2008 • GTC Biotherapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Executive Change in Control Agreement (this “Agreement”) is dated as of July 23, 2008 by and between GTC Biotherapeutics, Inc. (the “Company”), a Massachusetts corporation with its principal executive offices at 175 Crossing Boulevard, 4th Floor, Suite 410, Framingham, MA 01702-9322; and Harry M. Meade (“Executive”) hereby amends and restates in its entirety that Executive Change in Control Agreement dated August 16, 2004 between the Company and the Executive.
AMENDED AND RESTATED EXECUTIVE CHANGE IN CONTROL AGREEMENTExecutive Change in Control Agreement • August 7th, 2008 • GTC Biotherapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
This Amended and Restated Executive Change in Control Agreement (this “Agreement”) is dated as of July 23, 2008 by and between GTC Biotherapeutics, Inc. (the “Company”), a Massachusetts corporation with its principal executive offices at 175 Crossing Boulevard, 4th Floor, Suite 410, Framingham, MA 01702-9322; and Daniel S. Woloshen (“Executive”) hereby amends and restates in its entirety that Executive Change in Control Agreement dated August 16, 2004 between the Company and the Executive.
EXECUTIVE CHANGE IN CONTROL AGREEMENTExecutive Change in Control Agreement • August 3rd, 2006 • GTC Biotherapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
This Executive Change in Control Agreement (this “Agreement”) is dated as of , 200 by and between GTC Biotherapeutics, Inc. (the “Company”), a Massachusetts corporation with its principal executive offices at 175 Crossing Boulevard, 4th Floor, Suite 410, Framingham, MA 01702-9322; and (“Executive”).
EXECUTIVE CHANGE IN CONTROL AGREEMENTExecutive Change in Control Agreement • November 10th, 2004 • GTC Biotherapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
This Executive Change in Control Agreement (this “Agreement”) is dated as of August 16, 2004 by and between GTC Biotherapeutics, Inc. (the “Company”), a Massachusetts corporation with its principal executive offices at 175 Crossing Boulevard, 4th Floor, Suite 410, Framingham, MA 01702-9322; and Gregory F. Liposky (“Executive”).
EXECUTIVE CHANGE IN CONTROL AGREEMENTExecutive Change in Control Agreement • November 10th, 2004 • GTC Biotherapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
This Executive Change in Control Agreement (this “Agreement”) is dated as of August 16, 2004 by and between GTC Biotherapeutics, Inc. (the “Company”), a Massachusetts corporation with its principal executive offices at 175 Crossing Boulevard, 4th Floor, Suite 410, Framingham, MA 01702-9322; and Daniel S. Woloshen (“Executive”).
EXECUTIVE CHANGE IN CONTROL AGREEMENTExecutive Change in Control Agreement • November 10th, 2004 • GTC Biotherapeutics Inc • Biological products, (no disgnostic substances) • Massachusetts
This Executive Change in Control Agreement (this “Agreement”) is dated as of August 16, 2004 by and between GTC Biotherapeutics, Inc. (the “Company”), a Massachusetts corporation with its principal executive offices at 175 Crossing Boulevard, 4th Floor, Suite 410, Framingham, MA 01702-9322; and Harry M. Meade, Ph.D. (“Executive”).
